Evidence map›Paper›PMID 32104426›Full record

ArticleAsian journal of pharmaceutical sciences2018

Enhanced transdermal delivery of meloxicam by nanocrystals: Preparation,

Qin Yu, Xiying Wu, Quangang Zhu, Wei Wu, Zhongjian Chen, Ye Li, Yi Lu

Abstract read
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. High-Payload Nanosuspension ofInternational journal of nanomedicine · 2021
    Article
  15. Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: Potential for enhanced treatment of psoriasis.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qin YuShanghai Dermatology Hospital, Shanghai 200443, China.
Xiying WuShanghai Dermatology Hospital, Shanghai 200443, China.
Quangang ZhuShanghai Dermatology Hospital, Shanghai 200443, China.
Wei WuShanghai Dermatology Hospital, Shanghai 200443, China.
Zhongjian ChenShanghai Dermatology Hospital, Shanghai 200443, China.
Ye LiShaanxi Academy of Traditional Chinese Medicine, Xi'an 710003, China.
Yi LuShanghai Dermatology Hospital, Shanghai 200443, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meloxicam (MLX) is efficient in relieving pain and inflammatory symptoms, which, however, is limited by the poor solubility and gastrointestinal side effects. The objective of this study is to develop a nanocrystal formulation to enhance transdermal delivery of MLX. MLX nanocrystals were successfully prepared by the nanoprecipitation technique based on acid-base neutralization. With poloxamer 407 and Tween 80 (80/20, w/w) as mixed stabilizers, MLX nanocrystals with particle size of 175 nm were obtained. The crystalline structure of MLX nanocrystals was confirmed by both differential scanning calorimetry and X-ray powder diffractometry. However, the nanoprecipitation process reduced the crystallinity of MLX. Nanocrystals increased both

Indexed as

Acid-base neutralizationMeloxicamNanocrystalsNanoprecipitationTransdermal delivery

Identifiers

PMID32104426
PMCPMC7032118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.